Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412760 · ClinicalTrials.gov registry record · NA
Hydrops: Diagnosing & Redefining Outcomes With Precision Study
A NA study of Birth Defect and Fetal Anomaly, sponsored by University of California, San Francisco.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT03412760 is a NA study of Birth Defect and Fetal Anomaly that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03412760, a NA study of Birth Defect and Fetal Anomaly, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a national, prospective study designed to investigate the genetic etiologies of non-immune hydrops fetalis (NIHF) and other birth defects. At least half of prenatally diagnosed NIHF cases remain of unknown etiology after standard work up, and a substantial proportion of other birth defects remain of unknown etiology as well. The investigators are performing exome sequencing (ES) for the affected fetus or neonate in unexplained cases, as well as enrolling cases with a genetic explanation to represent the full spectrum of diseases underlying NIHF and other birth defects.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Exome sequencing
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2027-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03412760
The ClinicalTrials.gov registry entry for NCT03412760 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Birth Defect appearing as the primary indexed condition, and to 1 intervention - of which Exome sequencing is the first listed.
NCT03412760 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03412760 about?
NCT03412760 is a clinical study titled "Hydrops: Diagnosing & Redefining Outcomes With Precision Study". This is a national, prospective study designed to investigate the genetic etiologies of non-immune hydrops fetalis (NIHF) and other birth defects. At least half of prenatally diagnosed NIHF cases remain of unknown etiology after standard work up, and a substantial proportion of other birth defects r...
What is the current status of trial NCT03412760?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2018-10-11. Estimated completion is 2027-02.
What conditions does trial NCT03412760 study?
This clinical trial studies the following conditions: Birth Defect, Fetal Anomaly, Hydrops Fetalis.
What interventions are being tested in trial NCT03412760?
The interventions under investigation include: Exome sequencing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03412760?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03412760 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Birth Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.